Fig. 7 |. BML-210 treatment enhances antitumour responses in combination with PD-1 blockade.

a, Analysis of immune profile and microenvironment of the mouse EO771 tumours in C57BL/6 mice treated with control or BML-210 using a CyTOF panel containing 27 markers (Supplementary Table 2). tSNE representation of the immune cell subtypes and percentages of distinct immune cell populations in the tumours are shown. b,c, tSNE representation and quantitative analysis of CD8⁺ T cells (b) and PMN-MDSCs (CD11b⁺Ly6G⁺Ly6C^lowF4/80⁻) (c) in the EO771 tumours with control or BML-210 treatment. The colour scale is specific for each channel. The dot plot is spectrum coloured for the indicated channel; the minimum and maximum values for the expression intensity are determined upon global expression using Cytobank. d-f, Gross dissected mammary tumour images (d), tumour growth (e) and weight (f) of the EO771 tumours from the tumour-bearing C57BL/6 mice treated with vehicle control, BML-210 (20 mg kg⁻¹), PD-1 antibody (200 μg per mouse), or BML-210 and PD-1 antibody combo. g,h, Histograms and quantitative results of CD8⁺ T cells and cleaved Caspase 3⁺ cells in the tumour tissues with indicated treatment. Each individual symbol in (g) and (h) represents the percentage of the positive cells from the total cells in an independent field. A total of 20 images in each group were analyzed to quantify the cell proportion. Two-sided Student’s t-test was performed for statistical analysis in (b,c). One-way ANOVA test was conducted for statistical analysis in (e,f,h). All the data are presented as mean ± SD. ***, p < 0.001; ****, p < 0.0001; ns, no significance.